Progress in endocrine therapy for early breast cancer.
10.11817/j.issn.1672-7347.2019.190289
- Author:
Peiting LI
1
;
Wei WU
1
;
Liyuan QIAN
1
;
Boni DING
1
;
Meng YANG
1
Author Information
1. Department of Breast Thyroid Surgery, Third Xiangya Hospital, Central South University, Changsha 410013, China.
- Publication Type:Journal Article
- MeSH:
Breast Neoplasms;
Humans;
Receptors, Estrogen
- From:
Journal of Central South University(Medical Sciences)
2019;44(11):1268-1274
- CountryChina
- Language:Chinese
-
Abstract:
Breast cancer is a malignant tumor that occurs in the epithelial tissues of the breast gland. The cause of the disease is not fully understood and may be related to genetic, endocrine and other factors. For estrogen or progesterone receptor-positive early breast cancer, endocrine therapy is efficient, simple, and fewer side-effect, so endocrine therapy plays an important role in the treatment for early breast cancer. But most of them will develop drug-resistant after 8 to 14 months and have to combine with chemotherapy or molecule targeted therapy. However, there are still different ideas in the effects of endocrine therapy drugs alone or in combination with chemotherapy or molecule targeted drugs, pre-menopausally or post-menopausally.
